Associated Papers
Atrial remodelling and dysfunction in hypertrophic cardiomyopathy: prognostic role and therapeutic target.
Piazzai C et al.
Frontiers in Cardiovascular Medicine, 2025
Connexin hemichannels as candidate targets for cardioprotective and anti-arrhythmic treatments.
Leybaert L et al.
The Journal of Clinical Investigation, 2023
Genetics of atrial fibrillation-an update of recent findings.
Manoharan A et al.
Molecular Biology Reports, 2022
Cytoskeletal Protein Variants Driving Atrial Fibrillation: Potential Mechanisms of Action.
van Wijk SW et al.
Cells, 2022
Atrial fibrillation-a complex polygenetic disease.
Andersen JH et al.
European Journal of Human Genetics : Ejhg, 2021
33279945 (PubMed )
Supplement: 41431_2020_784_MOESM3_ESM.xlsx › Sheet1
Insights into myosin regulatory and essential light chains: a focus on their roles in cardiac and skeletal muscle function, development and disease.
Sitbon YH et al.
Journal of Muscle Research and Cell Motility, 2020
Metastable Atrial State Underlies the Primary Genetic Substrate for MYL4 Mutation-Associated Atrial Fibrillation.
Ghazizadeh Z et al.
Circulation, 2020
Reevaluating the Mutation Classification in Genetic Studies of Bradycardia Using ACMG/AMP Variant Classification Framework.
Cheng L et al.
International Journal of Genomics, 2020
Rs4968309 in Myosin Light Chain 4 (MYL4) Associated With Atrial Fibrillation Onset and Predicts Clinical Outcomes After Catheter Ablation in Atrial Fibrillation Patients Without Structural Heart Disease.
Zhong Y et al.
Circulation Journal : Official Journal of the Japanese Circulation Society, 2019
A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation.
Gudbjartsson DF et al.
European Heart Journal, 2017
Large-scale whole-genome sequencing of the Icelandic population.
Gudbjartsson DF et al.
Nature Genetics, 2015
Select a paper to view details